EP4295904A3 - Use of glutamine synthetase for treating hyperammonemia - Google Patents
Use of glutamine synthetase for treating hyperammonemia Download PDFInfo
- Publication number
- EP4295904A3 EP4295904A3 EP23206416.2A EP23206416A EP4295904A3 EP 4295904 A3 EP4295904 A3 EP 4295904A3 EP 23206416 A EP23206416 A EP 23206416A EP 4295904 A3 EP4295904 A3 EP 4295904A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- glutamine synthetase
- relates
- hyperammonemia
- protein
- treating hyperammonemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000005396 glutamine synthetase Human genes 0.000 title abstract 6
- 108020002326 glutamine synthetase Proteins 0.000 title abstract 6
- 206010020575 Hyperammonaemia Diseases 0.000 title abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 238000009163 protein therapy Methods 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 229910021529 ammonia Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002516 radical scavenger Substances 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
- C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1708288.4A GB201708288D0 (en) | 2017-05-24 | 2017-05-24 | Use of glutamine synthetase for treating hyperammonemia |
GBGB1800867.2A GB201800867D0 (en) | 2018-01-19 | 2018-01-19 | Use of glutamine synthetase for treating hyperammonemia |
EP18728717.2A EP3630077A1 (en) | 2017-05-24 | 2018-05-24 | Use of glutamine synthetase for treating hyperammonemia |
PCT/GB2018/051415 WO2018215780A1 (en) | 2017-05-24 | 2018-05-24 | Use of glutamine synthetase for treating hyperammonemia |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18728717.2A Division EP3630077A1 (en) | 2017-05-24 | 2018-05-24 | Use of glutamine synthetase for treating hyperammonemia |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4295904A2 EP4295904A2 (en) | 2023-12-27 |
EP4295904A3 true EP4295904A3 (en) | 2024-02-28 |
Family
ID=62492675
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23206416.2A Pending EP4295904A3 (en) | 2017-05-24 | 2018-05-24 | Use of glutamine synthetase for treating hyperammonemia |
EP22176864.1A Pending EP4119133A1 (en) | 2017-05-24 | 2018-05-24 | Glutamine synthetase protein conjugate |
EP18728717.2A Pending EP3630077A1 (en) | 2017-05-24 | 2018-05-24 | Use of glutamine synthetase for treating hyperammonemia |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22176864.1A Pending EP4119133A1 (en) | 2017-05-24 | 2018-05-24 | Glutamine synthetase protein conjugate |
EP18728717.2A Pending EP3630077A1 (en) | 2017-05-24 | 2018-05-24 | Use of glutamine synthetase for treating hyperammonemia |
Country Status (11)
Country | Link |
---|---|
US (4) | US20210145946A1 (en) |
EP (3) | EP4295904A3 (en) |
JP (3) | JP2020520677A (en) |
KR (1) | KR20200018488A (en) |
CN (1) | CN111093641A (en) |
AU (2) | AU2018272294B2 (en) |
BR (1) | BR112019024750A2 (en) |
CA (1) | CA3064352A1 (en) |
IL (1) | IL270817A (en) |
MX (1) | MX2019014027A (en) |
WO (1) | WO2018215780A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020065082A1 (en) * | 2018-09-28 | 2020-04-02 | Thoeris Gmbh | Use of glutamine synthetase for treating fatty liver disease |
CN110133287B (en) * | 2019-05-22 | 2021-07-30 | 上海碧云天生物技术有限公司 | Protein extraction solution and application thereof |
WO2022005201A1 (en) | 2020-06-30 | 2022-01-06 | 경상국립대학교산학협력단 | Composition for preventing, ameliorating, or treating diseases caused by nitration of tyrosine in protein, containing tyrosine as active ingredient |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7590493B2 (en) | 2000-07-31 | 2009-09-15 | Ocimum Biosolutions, Inc. | Methods for determining hepatotoxins |
US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
US6451547B1 (en) | 2001-04-25 | 2002-09-17 | Syn X Pharma | Process for differential diagnosis of Alzheimer's dementia and device therefor |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
AUPR805101A0 (en) | 2001-10-03 | 2001-10-25 | University Of New South Wales, The | A method of genetic screening using an amplifiable gene |
JP2003225093A (en) | 2001-11-30 | 2003-08-12 | Sumitomo Pharmaceut Co Ltd | Marker for cartilage disorder and use thereof |
US6875792B2 (en) | 2002-01-31 | 2005-04-05 | Mso Pharma Llc | Dosage form of L-Methionine S-Sulfoximine |
JP2003274963A (en) | 2002-03-22 | 2003-09-30 | Japan Science & Technology Corp | Gene recombinant cell strain and liver function supporting equipment using the same |
US20050074865A1 (en) * | 2002-08-27 | 2005-04-07 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
EP1578996A4 (en) | 2002-10-18 | 2007-12-19 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
AU2003269876A1 (en) | 2003-05-21 | 2005-01-21 | Divergence, Inc | Nematode GS-like sequences |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20070098702A1 (en) * | 2005-02-17 | 2007-05-03 | University Of Maryland, Baltimore | Recombinant protein polymer vectors for systemic gene delivery |
EP1752143A1 (en) | 2005-08-08 | 2007-02-14 | NewThera | Novel uses for drugs targeting glutamine synthetase |
ES2672205T3 (en) | 2005-12-21 | 2018-06-13 | Université Catholique de Louvain | Liver Stem Cells Isolated |
RU2362572C2 (en) | 2007-07-17 | 2009-07-27 | Юрий Георгиевич Каминский | Way of depression of concentration of ammonia in blood by means of ammocytes and incapsulated glutamin synthetase |
EP2330892B1 (en) * | 2008-04-29 | 2016-06-29 | Horizon Therapeutics, Inc. | Methods of treatment using ammonia-scavenging drugs |
CN102177235A (en) | 2008-09-08 | 2011-09-07 | 赛莱克蒂斯公司 | Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof |
RU2012157572A (en) * | 2010-05-28 | 2014-07-10 | МЕН-ЭнЭрЖ СА | NEYREGULIN ISOFORM, NEUREGULIN POLYPEPTIDES AND THEIR APPLICATION |
WO2013020914A1 (en) * | 2011-08-10 | 2013-02-14 | Celares Gmbh | Peg-conjugated peptides |
US9567577B2 (en) | 2012-03-12 | 2017-02-14 | Ares Trading S.A. | Expression vector comprising a polynucleotide encoding a modified glutamine synthetase and a method for preparing a target protein employing the same |
EP2674495A1 (en) | 2012-06-14 | 2013-12-18 | Sanofi | CHO expression system |
MX2014013566A (en) | 2014-11-07 | 2016-05-09 | Inst Nac De Ciencias Medicas Y Nutricion Salvador Zubiran | Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases. |
AU2015353703B2 (en) | 2014-11-24 | 2021-04-01 | Ucl Business Plc | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
JP6817966B2 (en) * | 2015-06-10 | 2021-01-20 | シンロジック オペレーティング カンパニー インコーポレイテッド | Bacteria engineered to treat diseases associated with hyperammonemia |
US20190078099A1 (en) | 2016-03-30 | 2019-03-14 | Spark Therapeutics, Inc. | Cell line for recombinant protein and/or viral vector production |
CN109219660B (en) | 2016-05-11 | 2023-01-06 | 美国安进公司 | Direct selection of cells expressing high levels of heteromultimers using complementary vectors in the glutamine synthetase gene |
US20190352631A1 (en) | 2016-11-16 | 2019-11-21 | Agency For Science Technology And Research | Attenuated Glutamine Synthetase as a Selection Marker |
EP3638777A4 (en) | 2017-07-13 | 2021-05-12 | Memphis Meats, Inc. | Compositions and methods for increasing the efficiency of cell cultures used for food production |
US11713468B2 (en) | 2017-08-02 | 2023-08-01 | Dna Twopointo Inc. | DNA vectors and elements for sustained gene expression in eukaryotic cells |
CN109988777A (en) | 2017-12-29 | 2019-07-09 | 南京金斯瑞生物科技有限公司 | Glutamine synthetase gene and application |
CN110714057A (en) | 2018-07-11 | 2020-01-21 | 成都金洛克生物技术有限公司 | Universal FISH probe for detecting exogenous gene integration and positioning and application thereof |
CN109504709B (en) | 2018-11-28 | 2020-07-24 | 上海安民生物技术有限公司 | Albumin expression vector driven by albumin promoter |
WO2020227206A1 (en) | 2019-05-07 | 2020-11-12 | Amgen Inc. | Vectors and expression systems for producing recombinant proteins |
-
2018
- 2018-05-24 CA CA3064352A patent/CA3064352A1/en active Pending
- 2018-05-24 EP EP23206416.2A patent/EP4295904A3/en active Pending
- 2018-05-24 CN CN201880049768.4A patent/CN111093641A/en active Pending
- 2018-05-24 EP EP22176864.1A patent/EP4119133A1/en active Pending
- 2018-05-24 WO PCT/GB2018/051415 patent/WO2018215780A1/en active Application Filing
- 2018-05-24 AU AU2018272294A patent/AU2018272294B2/en active Active
- 2018-05-24 JP JP2020515296A patent/JP2020520677A/en active Pending
- 2018-05-24 US US16/616,884 patent/US20210145946A1/en active Pending
- 2018-05-24 KR KR1020197038087A patent/KR20200018488A/en not_active Application Discontinuation
- 2018-05-24 EP EP18728717.2A patent/EP3630077A1/en active Pending
- 2018-05-24 BR BR112019024750A patent/BR112019024750A2/en unknown
- 2018-05-24 MX MX2019014027A patent/MX2019014027A/en unknown
-
2019
- 2019-11-21 IL IL270817A patent/IL270817A/en unknown
-
2022
- 2022-06-03 US US17/832,564 patent/US20220401532A1/en active Pending
- 2022-06-03 US US17/832,562 patent/US11932885B2/en active Active
-
2023
- 2023-03-10 JP JP2023038030A patent/JP2023085301A/en active Pending
- 2023-10-30 US US18/497,740 patent/US20240150746A1/en active Pending
-
2024
- 2024-02-20 AU AU2024201089A patent/AU2024201089A1/en active Pending
- 2024-02-26 JP JP2024026784A patent/JP2024059833A/en active Pending
Non-Patent Citations (3)
Title |
---|
H 7 NAO ET AL: "VANCOUVER GENERAL HOSPITAL CSU PHARMACEUTICAL SCIENCES SPECIAL ACCESS PROGRAM (SAP) DRUG DATA SHEET DRUG NAME ALTERNATE NAME Sodium Phenylacetate / Sodium Benzoate (SA/SB) C 8 * REPORT ANY ADVERSE DRUG REACTIONS TO CSU PHARMACEUTICAL SCIENCES", 1 July 2007 (2007-07-01), XP055499951, Retrieved from the Internet <URL:http://www.vhpharmsci.com/pdtm/Drug%20Data%20Sheets%20-%20SAP%20&%20NF/Sodium%20Phenylacetate-Sodium%20Benzoate%20SAP.pdf> [retrieved on 20180815] * |
M A TORRES-VEGA ET AL: "Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia", GENE THERAPY, vol. 22, no. 1, 23 October 2014 (2014-10-23), GB, pages 58 - 64, XP055499916, ISSN: 0969-7128, DOI: 10.1038/gt.2014.89 * |
MIGUEL A TORRES-VEGA: "Reduction of Hyperammonemia In Vitro and In Vivo by a Baculovirus-Delivered Glutamine Synthetase as a New Approach for the Treatment of Hepatic Encephalopathy", BLOOD REVIEWS, vol. 30, no. 5, 1 May 2013 (2013-05-01), AMSTERDAM, NL, XP055499936, ISSN: 0268-960X * |
Also Published As
Publication number | Publication date |
---|---|
IL270817A (en) | 2020-01-30 |
EP4295904A2 (en) | 2023-12-27 |
AU2018272294A1 (en) | 2020-01-16 |
KR20200018488A (en) | 2020-02-19 |
JP2024059833A (en) | 2024-05-01 |
US20210145946A1 (en) | 2021-05-20 |
CA3064352A1 (en) | 2018-11-29 |
JP2020520677A (en) | 2020-07-16 |
MX2019014027A (en) | 2020-08-03 |
EP3630077A1 (en) | 2020-04-08 |
AU2018272294B2 (en) | 2024-05-23 |
WO2018215780A1 (en) | 2018-11-29 |
US20220401531A1 (en) | 2022-12-22 |
JP2023085301A (en) | 2023-06-20 |
BR112019024750A2 (en) | 2020-06-09 |
EP4119133A1 (en) | 2023-01-18 |
US20240150746A1 (en) | 2024-05-09 |
AU2024201089A1 (en) | 2024-03-14 |
US20220401532A1 (en) | 2022-12-22 |
CN111093641A (en) | 2020-05-01 |
US11932885B2 (en) | 2024-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
MX2017013983A (en) | Use of active agents during chemical treatments. | |
MY197635A (en) | Benzooxazole derivatives as immunomodulators | |
WO2015151079A3 (en) | Auristatin analogues and their conjugates with cell-binding molecules | |
MX2019011219A (en) | Rapid and controlled delivery of compositions with restored entourage effects. | |
WO2017218981A3 (en) | Compositions and methods for reducing ocular neovascularization | |
EP4295904A3 (en) | Use of glutamine synthetase for treating hyperammonemia | |
WO2019067666A8 (en) | Therapeutic methods relating to hsp90 inhibitors | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
WO2009109927A3 (en) | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer | |
GB2541835A (en) | Multivesicular liposome formulations of tranexamic acid | |
MX2019009227A (en) | Methods for treating cancer using hsp90 inhibitors. | |
WO2018042438A3 (en) | Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders | |
MY200975A (en) | "Compositions Comprising Amino acids for use in the Treatment of Mitochondrial Dysfunction-Related Diseases" | |
WO2018143552A3 (en) | Injectable composition for preventing hair loss or stimulating hair growth | |
EP4289822A3 (en) | Benzoimidazol-1,2-yl amides as kv7 channel activators | |
EP3069720A8 (en) | Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases | |
WO2018085574A3 (en) | Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof | |
MX2021002916A (en) | Deuterium-enriched pirfenidone and methods of use thereof. | |
EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
EP4342473A3 (en) | Compounds useful in hiv therapy | |
WO2008112773A3 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension | |
MY193536A (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
WO2016177908A3 (en) | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3630077 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0003000000 Ipc: A61K0031000000 |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/10 20060101ALI20240124BHEP Ipc: A61K 38/43 20060101ALI20240124BHEP Ipc: A61K 31/00 20060101AFI20240124BHEP |